SCHEMBL321431

SCHEMBL321431

COC(=O)[C@@H](N)CCC(N)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.56
BLM P54132 1/20 0.56
PMP22 Q01453 1/20 0.56
KMT2A Q03164 1/20 0.56
DPP4 P27487 2/20 0.49
DPP8 Q6V1X1 2/20 0.49
DPP9 Q86TI2 2/20 0.49
LTA4H P09960 3/20 0.42
FOLH1 Q04609 1/20 0.41
SLC1A1 P43005 2/20 0.38
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GSR P00390 1/20 0.37
CYP1A2 P05177 1/20 0.37
GRIK1 P39086 1/20 0.37
GRM5 P41594 1/20 0.37
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716803 1.00 ALOX15 (0.56) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL10192702 1.00 ALOX15 (0.56) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL2082961 1.00 ALOX15 (0.56) ALOX15BLMPMP22KMT2ADPP4
Hydrochloric Acid SCHEMBL595131 0.98 ALOX15 (0.54) ALOX15BLMPMP22KMT2ADPP4
Hydrochloric Acid SCHEMBL2083204 0.98 ALOX15 (0.54) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL10633429 0.91 ALOX15 (0.47) ALOX15BLMPMP22KMT2ADPP4
Glutamic Acid SCHEMBL19128265 0.88 ALOX15 (0.63) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL11776470 0.84 SMN1; SMN2 (0.42) LTA4HSLC1A1CA1CA2SMN1; SMN2
SCHEMBL12601005 0.83 LTA4H (0.40) ALOX15BLMPMP22KMT2ADPP4
SCHEMBL18870212 0.83 ALOX15 (0.52) ALOX15BLMPMP22KMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116199643-A Phenothiazine compound containing isopropanol substructure, and preparation and application thereof 贵州大学 2023-06-02 CN claimed
CN-110407807-A A kind of preparation method of lenalidomide GANSU TAISHENG CHEMICAL TECH CO LTD 2019-11-05 CN claimed
CN-102892425-A Treatment of cardiac conditions ZEALAND PHARMA AS 2013-01-23 CN claimed
CN-101116654-B Use of ellagic acid for treating whitening of the hair OREAL 2012-11-21 CN claimed
CN-101591375-B Compound with analgesic activity, preparation method and application thereof UNIV CAPITAL MEDICAL 2011-11-09 CN claimed
CN-101190895-B N-[(3S)-1,2,3,4-tetrahydroisoquinolino-3-formacyl]amino acid, preparation method and application thereof CAPITAL UNIVERSITY OF MEDICAL SCIENCES 2010-05-26 CN claimed
CN-101665484-A Method for preparing lenalidomide SHANGHAI HAOYUAN CHEMEXPRESS B 2010-03-10 CN claimed
CN-101591375-A Has compound of analgesic activities and its production and application UNIV CAPITAL MEDICAL (CN) 2009-12-02 CN claimed
CN-1429097-A Use of ellagic acid as anti-pollution cosmetic agent OREAL (FR) 2003-07-09 CN claimed
EP-4673146-A2 METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS Biohaven Therapeutics Ltd. (VG) 2026-01-07 EP disclosed
US-20250381155-A1 USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION UNIV VANDERBILT (US) 2025-12-18 US disclosed
EP-4662213-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINES AND USES THEREOF Verge Analytics, Inc. (US) 2025-12-17 EP disclosed
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-11 US disclosed
US-12492280-B2 Process for producing a polyurethane composition BASF SE (DE) 2025-12-09 US disclosed
US-5350748-A 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion WARNER-LAMBERT COMPANY (US) 1994-09-27 US disclosed
CN-1079473-A The N-phosphinylidyne small peptide UNIV QINGHUA (CN) 1993-12-15 CN disclosed
EP-0485517-A1 SYNTHESIS OF GLYCOSIDES HAVING PREDETERMINED STEREOCHEMISTRY YALE UNIVERSITY (US) 1992-05-20 EP disclosed
WO-1991002739-A1 SYNTHESIS OF GLYCOSIDES HAVING PREDETERMINED STEREOCHEMISTRY YALE UNIVERSITY (US) 1991-03-07 WO disclosed
US-4766110-A INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS RYAN JAMES W (US) 1988-08-23 US disclosed
EP-0073143-A2 Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides Ryan, James Walter (US) 1983-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ALOX15 4053/4885BLM 1482/4885PMP22 3333/4885
US-20250381155-A1 USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION SIRT3, SIRT2, GLS ALOX15 2840/4885BLM 2932/4885PMP22 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.